Bio-Bridge Science Completes Acquisition of Xinheng Baide Biotechnology Co. Ltd.

  
    
  
  
    
      Bio-Bridge Science, Inc. (OTCBB:BGES), a biotechnology company engaged 
      in the commercial development of vaccines for the prevention and 
      treatment of human infectious diseases announced today that its 
      wholly-owned subsidiary, Bio-Bridge Science (HK) Co., Ltd. closed the 
      acquisition of Xinheng Baide Biotechnology Co. Ltd.(the “Seller” 
      or “Xinheng Baide”), 
      a serum manufacturing company organized under the laws of the PRC, 
      pursuant to which BGES purchased newly issued shares of Seller. BGES now 
      controls 51% of the outstanding capital stock of the Seller. The total 
      cash purchase price for the shares is RMB 6 million (approximately US$ 
      881,047). Xinheng Baide, located in the city of Huhhot in Inner Mongolia 
      of the People’s Republic of China, 
      manufactures and distributes bovine serum and other related products 
      primarily in China. Bovine serum is used in vaccine production as well 
      as scientific research. Subsequent to the closing today, audited 
      financials of Xinheng Baide will be filed with the Securities and 
      Exchange Commission within the time frame stipulated.
    
    
      “We are pleased to see the completion of the 
      acquisition of Xinheng Baide,” said Dr. Liang 
      Qiao, Chairman and CEO of Bio-Bridge Science. “We 
      expect Xinheng Baide to grow significantly in the future from the 
      synergies of both parties as well as the expected increase in the demand 
      for serum in China. Xinheng Baide fits into our strategic plan by 
      providing a potential steady, while growing, source of revenues to us, 
      as well as providing a new distribution channel for our products. The 
      acquisition of Xinheng Baide represents our dedication to our strategic 
      plan and to bringing value to our shareholders.”
    
    
      This press release contains forward-looking statements. Forward-looking 
      statements include statements concerning plans, objectives, goals, 
      strategies, future events or performance, and underlying assumptions and 
      other statements that are other than statements of historical facts. 
      These statements are subject to uncertainties and risks including, but 
      not limited to, product and service demand and acceptance, changes in 
      technology, economic conditions, the impact of competition and pricing, 
      government regulation, and other risks defined in this document and in 
      statements filed from time to time with the Securities and Exchange 
      Commission. All such forward-looking statements, whether written or 
      oral, and whether made by or on behalf of the company, are expressly 
      qualified by these cautionary statements and any other cautionary 
      statements which may accompany the forward-looking statements. In 
      addition, the company disclaims any obligation to update any 
      forward-looking statements to reflect events or circumstances after the 
      date hereof. Please refer to the Company's SEC filings for additional 
      information.